Data from treatment of UCD cases in published literature and ACCELERATE registry
| Therapy . | Published literature, n (%)* . | Ongoing CD natural history study, n (%)† . |
|---|---|---|
| Surgical resection‡ | 457 | 39 |
| Evaluable | 237 | 37 |
| Response§ | 228 (96.2) | 31 (83.8) |
| Nonresponse‖ | 9 (3.8) | 6 (16.2) |
| Nonevaluable | 220 | 2 |
| Embolization | 2 | 0 |
| Evaluable | 1 | 0 |
| Response§ | 1 (100) | 0 |
| Nonresponse‖ | 0 | 0 |
| Nonevaluable | 1 | 0 |
| Rituximab ± steroids | 5 | 9 |
| Evaluable | 4 | 8 |
| Response§ | 2 (50.0) | 6 (75.0) |
| Nonresponse‖ | 2 (50.0) | 2 (25.0) |
| Nonevaluable | 1 | 1 |
| Radiotherapy | 15 | 1 |
| Evaluable | 8 | 1 |
| Response§ | 8 (100) | 1 (100) |
| Nonresponse‖ | 0 | 0 |
| Nonevaluable | 7 | 0 |
| Therapy . | Published literature, n (%)* . | Ongoing CD natural history study, n (%)† . |
|---|---|---|
| Surgical resection‡ | 457 | 39 |
| Evaluable | 237 | 37 |
| Response§ | 228 (96.2) | 31 (83.8) |
| Nonresponse‖ | 9 (3.8) | 6 (16.2) |
| Nonevaluable | 220 | 2 |
| Embolization | 2 | 0 |
| Evaluable | 1 | 0 |
| Response§ | 1 (100) | 0 |
| Nonresponse‖ | 0 | 0 |
| Nonevaluable | 1 | 0 |
| Rituximab ± steroids | 5 | 9 |
| Evaluable | 4 | 8 |
| Response§ | 2 (50.0) | 6 (75.0) |
| Nonresponse‖ | 2 (50.0) | 2 (25.0) |
| Nonevaluable | 1 | 1 |
| Radiotherapy | 15 | 1 |
| Evaluable | 8 | 1 |
| Response§ | 8 (100) | 1 (100) |
| Nonresponse‖ | 0 | 0 |
| Nonevaluable | 7 | 0 |
See supplemental Table 1.
Includes patients enrolled by CD-treating physicians at experienced centers in Europe or patients who self-enrolled and whose cases were reviewed by a panel of CD-treating clinicians and pathologists.
Includes complete or partial resection of lymph node.
Achieving at least 50% improvement of associated symptoms and at least 50% reduction of mass.
Achieving <50% improvement of associated symptoms or <50% reduction of mass.